Gilead Details Its HCV Dominance As AbbVie Seeks Meaningful Market Position
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. continues to maintain a dominant share in the hepatitis C market, while AbbVie Inc. tries to capitalize on a subordinate but still viable position in the indication. Gilead provided some granularity during its July 28 earnings call on how it has built such a huge edge in HCV sales and what its next tasks are, just as AbbVie used its July 24 call to assure investors it still has room to grow. The latter hopes an imminent Japanese approval and a second-generation regimen will boost its HCV business.
You may also be interested in...
Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine
Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.
Viking’s Oral Weight-Loss Drug Shows Early Efficacy/Safety Promise
An oral formulation of the GLP-1/GIP analog VK2735 showed up to 5.3% reduction in body weight after four weeks in a Phase I study, with a nearly pristine safety and tolerability profile.
Axsome Succeeds In Narcolepsy Phase III, But Is That Enough?
Analysts say reboxetine looks approvable for cataplexy related to narcolepsy, but debate how broadly the drug may be adopted in a generic-laden therapeutic space.